Company Overview of TaiRx, Inc.
TaiRx, Inc., a pharmaceutical company, focuses on the development of therapeutics with unmet medical needs. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase I clinical trial; and Rexis, an add-on injection therapy that is in Phase III clinical trials to treat patients with sepsis. Its pre-clinical products comprise TRX-606 that is used to enhance the drug absorption. The company was founded in 2011 and is based in Taipei City, Taiwan.
No. 66, San-Chung Road
Nankang Business Park
Taipei City, 11502
Founded in 2011
886 2 2653 5007
886 2 2653 5008
Key Executives for TaiRx, Inc.
TaiRx, Inc. does not have any Key Executives recorded.
Similar Private Companies By Industry
|ACRO Biomedical Co., Ltd.||Asia|
|Advanced Gene Technology Corporation||Asia|
|Akribio Co., Ltd.||Asia|
|Aprinoia Therapeutics Inc.||Asia|
|Asia Celera Genomics Corp.||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact TaiRx, Inc., please visit www.trx.com.tw. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.